Baricitinib in the Treatment of Patients with COVID-19: A Review of International Data and Analysis of Clinical Results in the Russian Population

Baricitinib in the Treatment of Patients with COVID-19: A Review of International Data and Analysis of Clinical Results in the Russian Population

The effects of baricitinib, a selective reversible inhibitor of Janus kinase 1 and 2, in the treatment of COVID-19 are associated with different aspects of pathogenesis — inhibition of viral endocytosis, reduction of excessive inflammatory response, and mitigation of vascular and pulmonary damage, whic...

Full description

Saved in:
Bibliographic Details
Main Authors: А. I. Zagrebneva, Е. А. Baryakh, Е. I. Zhelnova, N. G. Poteshkina, I. Р. Beloglazova, Z. Yu. Mutovina, I. V. Samsonova, Е. А. Kovalevskaya, V. V. Parshin, V. V. Pshenichnikova, D S. Fomina, Т. S. Kruglova, М. А. Lysenko, М. А. Dranitsyna
Format: Article
Language:Russian
Published: LLC "Publishing House OKI" 2021-05-01
Series:Антибиотики и Химиотерапия
Subjects:
covid-19, pneumonia, therapy, baricitinib
Online Access:https://www.antibiotics-chemotherapy.ru/jour/article/view/793
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.antibiotics-chemotherapy.ru/jour/article/view/793

Similar Items